Overview

The Treatment of Acute Gastrointestinal Injury Via Ultrasound-guided Erector Spinae Plane Block

Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
0
Participant gender:
All
Summary
In this single-center, randomized, parallel control clinical trial, patients will be randomly assigned to two groups. The treatment group receives ultrasound-guided erector spinae plane block with routine treatment of Acute Gastrointestinal Injury (AGI) for 7 days or until transferred to the general ward, while the control group only receives routine treatment of AGI. The primary outcome is the cure and remission rate of AGI.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Zhujiang Hospital
Treatments:
Ropivacaine
Criteria
Inclusion Criteria:

1. AGI are diagnosed according to the diagnostic criteria proposed by European Society
Intensive Care Medicine (ESICM) in 2012 and the AGI grade great than or equal to II.

2. Age 18-80 years.

3. Expected length of stay longer than 3 days.

Exclusion Criteria:

1. Mean arterial pressure is still less than 65 millimeter of Mercury (mmHg) treated with
rehydration and vasoactive agents, or with the dosage of norepinephrine more than
0.5ug/kg/min.

2. Heart rates are less than 50 beats per minute or moderate and severe atrioventricular
block without pacemaker.

3. Primary gastrointestinal disease such as mechanical intestinal obstruction, massive
hemorrhage of gastrointestinal tract and gastrointestinal perforation.

4. Severe trauma of chest, abdomen or back. gastrointestinal tract surgery history.

5. Neuromuscular disorders.

6. Drug addiction, alcohol abuse, opioid or amphetamine dependence, or mental disorders.

7. Pregnancy.

8. Brain dead.

9. Malignant tumor, or end-stage cachexia.

10. With contraindications of the erector spinae plane block (ESPB), such as local
infection, Spinal diseases or immobilization.

11. Allergy to local anesthetics.

12. Significant abnormalities in blood coagulation parameters.

13. Without written informed consent.